Overview

MAP Study: Methotrexate and Adalimumab in Psoriasis

Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jeffrey J Crowley MD
Collaborator:
AbbVie
Treatments:
Adalimumab
Methotrexate